• Sulfachloropyridazine Shapes Cecal Microbiota in E. tenella

  2026-07-17

  This study provides the first integrated analysis of how sulfachloropyridazine and ethanamizuril, alone or in combination, modulate the cecal microbiota and metabolomic landscape in chickens acutely infected with Eimeria tenella. The findings reveal drug-specific effects on both microbial taxa and metabolic profiles, informing future research on poultry coccidiosis intervention and microbiome monitoring.

• Evaluating Sulfamonomethoxine Toxicity in Aquatic Organisms

  2026-07-17

  This study investigates the acute and chronic toxicity of the veterinary sulfonamide antibiotic sulfamonomethoxine (SMM) across five representative aquatic species from different trophic levels. The work provides quantitative toxicity thresholds and demonstrates the heightened sensitivity of microalgae, emphasizing the need for rigorous environmental monitoring and informed aquaculture management.

• Rosiglitazone (Brl-49653) in PPARγ Research: Protocols & Pit

  2026-07-16

  Rosiglitazone (Brl-49653) is the benchmark synthetic thiazolidinedione PPARγ agonist for dissecting adipogenesis, insulin sensitivity, and metabolic remodeling in cell and animal models. This guide delivers stepwise protocols, troubleshooting strategies, and critical insights from recent advances—empowering reproducible, next-generation type II diabetes research.

• LY2228820: Bridging Anti-Inflammatory and Anti-Angiogenic Re

  2026-07-16

  Explore how LY2228820, a selective p38 MAP kinase inhibitor, is redefining translational research at the intersection of inflammation and angiogenesis. This thought-leadership article for APExBIO unpacks the mechanistic rationale, evidence-backed utility, and strategic guidance for leveraging LY2228820 in advanced anti-inflammatory and cancer studies. Building on recent breakthroughs in airway stent technology and integrating scenario-driven best practices, the discussion empowers researchers to accelerate discovery from bench to bedside.

• Dual Recombinase Tracing Reveals No Postnatal Neo-oogenesis

  2026-07-15

  A recent study deployed dual recombinase-mediated genetic tracing to rigorously test whether new oocytes are generated after birth in mice. The findings demonstrate that neither physiological conditions nor busulfan-induced ovarian injury lead to postnatal neo-oogenesis, resolving a decades-long debate in reproductive biology.

• Bergenin Targets γδT17 Cells to Alleviate Psoriasis via PPAR

  2026-07-15

  This study identifies bergenin as a natural PPARγ agonist that selectively suppresses pathogenic γδT17 cells in psoriasis. Mechanistically, bergenin activates PPARγ to promote PROX1 ubiquitination and degradation, disrupting fatty acid oxidation and reducing IL-17A production, offering a distinct immunometabolic intervention for inflammatory skin disease.

• Strategic Apoptosis Detection: Annexin V-FITC/7-AAD in Trans

  2026-07-14

  Translational researchers face mounting complexity in decoding cell death pathways within oncology and drug development. This article synthesizes cutting-edge mechanistic insights from recent osteosarcoma apoptosis research with strategic guidance for assay selection and workflow optimization. By contextualizing the APExBIO Annexin V-FITC/7-AAD Apoptosis Kit within the competitive landscape, and referencing both primary literature and peer expert commentary, we delineate actionable pathways to bridge preclinical findings to robust clinical impact.

• Plk1 Regulation of p31comet Controls Mitotic Checkpoint Disa

  2026-07-14

  This study elucidates how Polo-like kinase 1 (Plk1) directly regulates the activity of p31comet during the disassembly of mitotic checkpoint complexes (MCC), a process essential for accurate chromosome segregation. By mapping Plk1-dependent phosphorylation events and demonstrating their functional consequences, the research advances our understanding of mitotic exit mechanisms and checkpoint fidelity.

• Oltipraz in MASLD Models: Protocols, Innovation, and Trouble

  2026-07-13

  Oltipraz, a potent Nrf2 pathway activator, is transforming MASLD research by bridging chemoprevention with autophagy and ferroptosis modulation. This article delivers actionable workflows, troubleshooting insights, and protocol innovations for maximizing translational impact in metabolic liver disease studies.

• Strategic β1 Blockade: Metoprolol Tartrate in Translational

  2026-07-13

  This thought-leadership article explores the mechanistic foundation, experimental application, and translational significance of Metoprolol Tartrate as a selective β1-adrenergic blocking agent. By integrating recent findings distinguishing β1-selective from nonselective β-blockade—especially in the context of cardiovascular and hematopoietic regeneration—this piece delivers actionable guidance for researchers seeking high-fidelity, clinically relevant models. Protocol parameters, evidence-based discussion, and strategic outlook are provided, with direct links to pivotal studies and APExBIO’s research-grade Metoprolol Tartrate.

• Nano-Zoledronate Reshapes Innate Immunity via Metabolic Targ

  2026-07-12

  Chen et al. demonstrate that nano-granulated zoledronate (Nano-ZD) redirects zoledronate to lymph node-resident innate immune cells, enabling precise metabolic reprogramming and markedly boosting vaccine-induced and antitumor immunity. Their findings establish the mevalonate–CoQ–OXPHOS/pyrimidine axis as a promising target for metabolic adjuvant design and highlight nanotechnology’s potential to enhance immune modulation.

• Bismuth Subsalicylate in GI Disorder Research: Workflows & T

  2026-07-10

  Bismuth Subsalicylate empowers researchers with robust inhibition of inflammation pathways and precise modeling of gastrointestinal disorder mechanisms. This guide delivers hands-on workflows, troubleshooting insights, and protocol optimization strategies, leveraging APExBIO’s high-purity formulation for reproducible, high-impact results.

• Deracoxib and Piroxicam Impact on Canine Osteosarcoma Cell V

  2026-07-09

  This study evaluated the cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cells in vitro, revealing that deracoxib has greater potency at inhibiting tumor cell viability compared to piroxicam. The findings inform potential adjunctive strategies in osteosarcoma management, with implications for future tumor targeting research.

• RNA Pol II Inhibition: Apoptotic Signaling Beyond Transcript

  2026-07-09

  Harper et al. reveal that cell death from RNA polymerase II (Pol II) inhibition is not a passive consequence of mRNA decay, but an active, apoptosis-initiating signaling event triggered by the loss of hypophosphorylated Pol IIA. This discovery reshapes the understanding of regulated cell death mechanisms in cancer research and informs more precise experimental approaches.

• Cefazedone (Refosporen): Translational Leverage for β-Lactam

  2026-07-08

  This thought-leadership article explores the unique mechanistic and translational value of Cefazedone (Refosporen), a first-generation cephalosporin antibiotic, with a strong focus on its β-lactamase resistance, robust antibacterial spectrum, and PK/PD optimization. Integrating evidence from comparative studies and advanced research protocols, it guides translational researchers toward reproducible, clinically relevant outcomes in the era of escalating antimicrobial resistance.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page